アブストラクト
| Title | 最新の薬物療法時代におけるTACE |
|---|---|
| Subtitle | 今月のテーマ (総説) 肝細胞癌に対する最新の薬物療法時代における各種治療法の現況と展望 |
| Authors | 上嶋一臣1) |
| Authors (kana) | |
| Organization | 1)近畿大学医学部消化器内科 |
| Journal | 日本消化器病学会雑誌 |
| Volume | 119 |
| Number | 5 |
| Page | 414-422 |
| Year/Month | 2022 / 5 |
| Article | 報告 |
| Publisher | 日本消化器病学会 |
| Abstract | 要旨: 肝細胞癌治療では, 全身薬物療法の発達により, 肝動脈化学塞栓療法(TACE)の適応条件が厳格になってきている. すなわち, 腫瘍量が少ないUp-to-7 INのような状況でのみ根治的TACEが施行される. さらには分子標的薬の併用でTACEの効果を最大化することが可能である. 一方, 腫瘍量が多いUp-to-7 OUTのような状況では, 壊死, 縮小効果の高いアテゾリズマブ・ベバシズマブ併用療法やレンバチニブなどを用いた全身薬物療法を行い, 奏効後にTACEを行う. Intermediate stageではTACEと薬物療法は相補的役割を果たしており, 腫瘍状態や肝予備能を考慮して治療方法を選択することが重要である. |
| Practice | 臨床医学：内科系 |
| Keywords | 全身薬物療法, TACE, Intermediate stage |
- 全文ダウンロード： 従量制、基本料金制の方共に770円(税込) です。
参考文献
- 1) Llovet JM, Ricci S, Mazzaferro V, et al : Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 ; 378-390 : 2008
- 2) Bruix J, Qin S, Merle P, et al : Regorafenib for pa-tients with hepatocellular carcinoma who pro-gressed on sorafenib treatment(RESORCE) : a randomised, double-blind, placebo-centrolled, phase 3 trial. Lancet 389 ; 56-66 : 2017
- 3) Kudo M, Finn RS, Qin S, et al : Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma : a ran-domised phase 3 non-inferiority trial. Lancet 391 ; 1163-1173 : 2018
- 4) Zhu AX, Kang YK, Yen CJ, et al : Ramucirumab after sorafeilib in patients with advanced hepato-cellular carcinoma and increased alpha-fetoprotein concentrations(REACH-2) : a random-ised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20 ; 282-296 : 2019
- 5) Finn RS, Qin S, Ikeda M, et al : Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med 382 ; 1894-1905 : 2020
残りの17件を表示する
- 6) Abou-Alfa GK, Meyer T, Cheng AL, et al : Cabo-zantinib in Patients with Advanced and Progress-ing Hepatocellular Carcinoma. N Engl J Med 379 ; 54-63 : 2018
- 7) 肝癌診療ガイドライン2021年版, 第5版, 日本肝臓学会編, 金原出版, 東京, 2021
- 8) Llovet JM, Villanueva A, Marrero JA, et al : Trial Design and Endpoints in Hepatocellular Carci-noma : AASLD Consensus Conference. Hepatol-ogy 73(suppl 1) ; 158-191 : 2021
- 9) Bruix J, Reig M, Sherman M : Evidence-Based Di-agnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. Gastroenterology 150 ; 835-853 : 2016
- 10) Bolondi L, Burroughs A, Dufour JF, et al : Hetero-geneity of patients with intermediate(BCLC B) Hepatocellular Carcinoma : proposal for a subclas-sification to facilitate treatment decisions. Semin Liver Dis 32 ; 348-359 : 2012
- 11) Kudo M, Arizumi T, Ueshima K, et al : Subclassifi-cation of BCLC B Stage Hepatocellular Carci-noma and Treatment Strategies : Proposal of Modified Bolondi's Subclassification(Kinki Crite-ria). Dig Dis 33 ; 751-758 : 2015
- 12) Kudo M, Matsui O, Izumi N, et al : Transarterial chemoembolization failure/refractoriness : JSH-LCSGJ criteria 2014 update. Oncology 87(suppl 1) ; 22-31 : 2014
- 13) Arizumi T, Ueshima K, Minami T, et al : Effec-tiveness of Sorafenib in Patients with Tran-scatheter Arterial Chemoembolization(TACE)Refractory and Intermediate-Stage Hepatocellu-lar Carcinoma. Liver Cancer 4 ; 253-262 : 2015
- 14) Ogasawara S, Chiba T, Ooka Y, et al : Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization. Oncology 87 ; 330-341 : 2014
- 15) Peck-Radosavljevic M, Raoul JL, Lee HC, et al : OPTIMIS : An international observational study to assess the use of sorafenib after transarterial chemoembolization(TACE)in patients with he-patocellular carcinoma(HCC). J Clin Oncol 32(suppl) ; TPS4155 : 2014
- 16) 肝癌診療マニュアル第4版, 日本肝臓学会編, 医学書院, 東京, 213-214 : 2020
- 17) Yamashita T, Kudo M, Ikeda K, et al : REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unre-sectable hepatocellular carcinoma : an analysis of Japanese subset. J Gastroenterol 55 ; 113-122 : 2020
- 18) Cheng AL, Qin S, Ikeda M, et al : Updated effi-cacy and safety data from IMbrave150 : Atezoli-zumab plus bevacizumab vs. sorafenib for unre-sectable hepatocellular carcinoma. J Hepatol 76 ; 862-873 : 2022
- 19) Jain RK : Normalization of tumor vasculature : an emerging concept in antiangiogenic therapy. Sci-ence 307 ; 58-62 : 2005
- 20) Kano MR, Komuta Y, Iwata C, et al : Comparison of the effects of the kinase inhibitors imatinib, sorafenib, and transforming growth factor-beta receptor inhibitor on extravasation of nanoparti-cles from neovasculature. Cancer Sci 100 ; 173-180 : 2009
- 21) Kudo M, Ueshima K, Ikeda M, et al : Randomised, multicentre prospective trial of transarterial chemoembolisation(TACE)plus sorafenib as compared with TACE alone in patients with he-patocellular carcinoma : TACTICS trial. Gut 69 ; 1492-1501 : 2020
- 22) Ueshima K, Ishikawa T, Saeki I, et al : Tran-scatheter arterial chemoembolization therapy in combination strategy with lenvatinib in patients with unresectable hepatocellular carcinoma(TACTICS-L)in Japan : primary analysis 2022. ASCO Gastrointestinal Cancers Symposium, American Society of Clinical Oncology, 2022
